MRK Rebound in sight MRK, along with many othe rpharma stocks has taken some serious beating.
But we like fear - as an opportunity- and it’s here( I dare say it) based on the bottom most will rejection, aka a shooting star.
So here are my forecasts in my crystal ball::
1. Overall Trend and Structure
• Longer-Term Trend: MRK peaked near the $115–$120 region in late 2022/early 2023 and has since been making lower highs and lower lows on the weekly timeframe. This suggests a downward bias over the past 12+ months.
• Recent Price Action: Price is hovering around the mid-$80s, testing support in the $80–$83 zone. This area held as support a few times in 2021–2022 and is now being revisited.
• Break of Structure (BOS) & Change of Character (CHoCH) Markers:
• The chart indicators label potential break-of-structure levels where bulls and bears exchanged control.
• Since late 2022, these BOS levels have mostly favored the bears, confirming the downtrend.
• A bullish CHoCH would require a strong close and sustained trading above the most recent swing high (somewhere in the $90–$92 zone on the weekly).
2. Key Technical Indicators
1. Stochastic Oscillator (Lower Panel)
• Appears oversold or near the lower region. On a weekly timeframe, this sometimes suggests that bearish momentum could be losing steam. A bullish crossover from oversold levels often points to a short-term rebound.
2. Momentum Oscillators (e.g., RSI/MACD, if present)
• While not explicitly shown, the lower indicator panel with wave-like patterns suggests momentum has been negative but may be stabilising.
3. Support & Resistance Levels
• Immediate Support: $80–$83 zone. A weekly close below $80 could open the door to the mid-$70s or even $70.
• Initial Resistance: $90–$92 (recent swing highs). Price needs to reclaim this region to confirm a potential bullish reversal on the weekly timeframe.
• Secondary Resistance: $95–$100. If the price clears $92, this would be the next zone of overhead supply from prior consolidation.
3. Possible Scenarios & Probability Estimates
Below are hypothetical scenarios with rough probability estimates, assuming no major market-wide shocks and stable macro conditions.
Bullish Reversal Scenario (Est. 55–60% probability)
1. Hold Support around $80–$83:
• If MRK holds above this region on a weekly closing basis, buyers may attempt a short-term bounce.
• Timeframe: Could take 2–5 weeks for a solid weekly close confirming support.
2. Upside Targets:
• First Target: $90–$92 (key swing high + psychological level).
• Second Target: $95–$100 if price breaks and holds above $92 on strong volume.
3. Catalysts to Watch:
• A weekly close above $92 would be a “change of character” from lower highs to a potential new uptrend on the weekly.
• Bullish crossover in the Stochastics or MACD on the weekly.
Continued Downtrend Scenario (Est. 40–45% probability)
1. Failure at $80 Support:
• If the stock breaks below $80 on a weekly close, the downtrend likely continues.
• Timeframe: A decisive break can happen within 1–3 weeks if sellers remain strong.
2. Downside Targets:
• First Target: $75 region, near previous support levels.
• Second Target: $70 if selling pressure accelerates and overall market sentiment remains weak.
3. Catalysts to Watch :
• Weak earnings, lowered guidance, or broader market declines.
• Stochastics remaining in oversold territory without crossing back up, indicating persistent downward momentum.
4. Trade Direction & Time Estimates
• Short-Term (1–4 weeks):
• Expect choppy price action around $80–$83. A near-term bounce is possible if momentum indicators turn bullish.
• If a bounce materialises, watch $90–$92 as a critical resistance.
• Medium-Term (2–3 months):
• If bulls successfully defend $80 and break $92, a run to $95–$100 could happen by mid-spring to early summer.
• Conversely, if $80 fails, the downtrend may persist into the $70s in a similar timeframe.
5. Risk Management Considerations
1. Confirm Volume & Momentum:
• Wait for a weekly close above (or below) key levels ($80 support or $92 resistance) to confirm the trend direction.
2. Position Sizing:
• If going long near $80 support, consider a stop-loss just below $80 (e.g., $78–$79) to limit risk.
• If anticipating a breakdown, watch for confirmation (weekly close below $80) before entering short positions.
3. News & Fundamentals:
• MRK is a large pharmaceutical company sensitive to drug approvals, patent news, and broader healthcare developments. Technicals alone might not capture sudden catalyst-driven moves.
Final Thoughts
• Most Likely Near-Term Path: A technical rebound attempt from $80–$83, but the stock must decisively clear $90–$92 to signal a genuine bullish reversal on the weekly chart.
• Overall Bias: The multi-month trend is still down, so the burden of proof is on bulls to show a structural change in character.
Again, these are probabilistic views.
Good luck out there
MERCK
MERCK_1W_BuyMerck & Company stock analysis on weekly and long-term time frames The market is in an upward trend and in an upward channel, and currently the price is at the bottom of the upward channel, and also the static number 100.00 is important, and as long as it can maintain this number as support, the trend is still upward. It can move towards the number 150.00. The growth percentage of this stock is 50%.
MRK Merck Options Ahead of EarningsAnalyzing the options chain and the chart patterns of MRK Merck prior to the earnings report this week,
I would consider purchasing the 127usd strike price Calls with
an expiration date of 2024-8-16,
for a premium of approximately $2.64.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Merck to Acquire Harpoon Therapeutics in $680M DealNavigating the Oncology Frontier with Harpoon Therapeutics Acquisition
In a significant strategic move, pharmaceutical giant Merck & Co. ( NYSE:MRK ) has announced its plans to acquire cancer drugmaker Harpoon Therapeutics Inc. ( NASDAQ:HARP ) in a transformative deal valued at $680 million. The move aims to solidify Merck's leadership position in the highly lucrative oncology space, diversifying its portfolio and positioning itself for sustained growth in the face of potential challenges for its flagship cancer immunotherapy, Keytruda.
The Deal Overview:
Merck's acquisition of Harpoon Therapeutics involves a payment of $23 per share, more than double Harpoon's last closing share price, signaling Merck's strong commitment to the strategic partnership. The deal is currently pending, awaiting approval from Harpoon shareholders, with the expected closure in the first half of 2024.
Keytruda and Beyond:
Merck's pursuit of Harpoon Therapeutics aligns with its broader strategy of seeking new sources of growth. With Keytruda generating a substantial $20.9 billion in 2022, Merck recognizes the importance of expanding its pipeline to maintain a competitive edge. Harpoon's promising early-stage trials and T-cell engager assets present Merck with an opportunity to diversify its oncology offerings and explore new avenues of therapeutic innovation.
Analyst Insights:
Merck's acquisition of Harpoon is a strategic and value-driven move. The early but promising data from Harpoon's T-cell engager assets, coupled with investor interest in similar technologies, positions Merck for potential growth in the oncology market.
Building a Robust Portfolio:
Merck's proactive approach to portfolio expansion is evident in its recent deals, including the acquisition of Daiichi Sankyo Co.'s experimental cancer drugs and the purchase of autoimmune drugmaker Prometheus. These moves showcase Merck's commitment to staying at the forefront of medical innovation and bolstering its position in key therapeutic areas.
Investor Sentiment and Momentum:
As evidenced by the stock's current trading position near the top of its 52-week range and above its 200-day simple moving average, investor sentiment towards Merck is positive.
Conclusion:
Merck's acquisition of Harpoon Therapeutics marks a pivotal moment in the pharmaceutical landscape, where innovation and strategic partnerships are crucial for sustained growth. By expanding its oncology portfolio with cutting-edge technologies, Merck positions itself as a leader in the fight against cancer, ensuring a robust pipeline and securing its role as a key player in the evolving healthcare landscape. As the deal progresses towards closure, investors and industry observers will keenly watch Merck's journey into a new era of therapeutic possibilities.
MRK SELLHi, according to my analysis of mrk stock. The stock looks negative. The stock broke the bottom at the 106 level. It also broke the ascending channel to the upside, as shown in the analysis. These are all indications that the stock is still under pressure from sellers. good luck for everbody
MERCK waves a strong short-term bullish flag.Merck and Company (MRK) is trading within a Channel Down since the May 03 High. Even though the price didn't touch the bottom (Lower Lows trend-line) of the Channel Down, having completed 4 straight green 1D candles indicates that most likely we have seen the new low of this sequence. Assuming the current bullish wave will make at least a +7.10% extension like the previous two, then we are only halfway there, so we still have a solid short-term buy opportunity in our hands.
As the 1D MACD is about to complete a Bullish Cross, the buy entry is validated. Our target is 108.00, still under the 1D MA200 (orange trend-line).
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
Merck: Water slide 🛝The pool-season is about to start, and Merck has already secured its place on the water slide, which should take it further downwards below the support at $110.66. However, there is still a 35% chance that the share might catch a bubbling fountain which could push it above the resistance at $119.65. In that case, we would expect Merck to develop a new top in the form of wave alt.B in green in the green zone between $119.87 and $123.79 first before turning downwards again.
MRK | Time for Puts | MerckMerck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Merck has Potential. MRKDivergent on the downside across multiple timeframes. Betting on a triangle B formation, now due for a C Wave to the upside. No confirmation yet. Speculating that this might be a very short term event.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
Merck & Company Analyze💊!!!Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. The company does business as Merck Sharp & Dohme outside the United States and Canada.
Merck was able to break the support lines. For now, it completed its pullback to support lines.
I expect that Merck will go down at least to the lower line of descending channel.
Merck & Company Analyze ( MRKUSD) Timeframe 4H⏰.
Do not forget to put Stop loss for your positions (For every position you want to open).
Please follow your strategy, this is just my idea, and I will be glad to see your ideas in this post.
Please do not forget the ✅' like '✅ button 🙏😊 & Share it with your friends; thanks, and Trade safe.
Merck and Company slowing down? Merck and Company
Short Term
We look to Sell at 93.34 (stop at 96.33)
We look to sell rallies. Price action looks to be forming a top. Although the bulls are in control, the stalling positive momentum indicates a turnaround is possible. There is scope for mild buying at the open but gains should be limited.
Our profit targets will be 86.55 and 83.96
Resistance: 92.00 / 95.00 / 100.00
Support: 86.50 / 83.50 / 80.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Merck heading down as well. MRKOne more huge pharma firm that is biting the dust. A giant flat with a C wave confirmed. No way but down on this one.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
6/20/22 MRKMerck & Company, Inc. ( NYSE:MRK )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $213.987B
Current Price: $84.62
Breakout price: $91.40
Buy Zone (Top/Bottom Range): $83.60-$79.90
Price Target: $103.20-$105.80
Estimated Duration to Target: 672-696d
Contract of Interest: $MRK 1/19/24 85c
Trade price as of publish date: $10.17/contract
Merck gaining momentum. MRKImmediate targets 85, 86. Invalidation at 76.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
Merck and Co. gearing for a boost. MRKAnd that's expected to an extent after a sizeable and quick drop. Merck did one, and fractally we are due to a rise that can potentially be viable percentage wise. But who knows what will happen.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
Undervalued Stock Series #3 : MERCKSeveral DCF valuations have suggested that the current price is on average +35% under the fair price.
I took a quick look at their financials : their income last 5 years is positive, their revenue have grown last 5 years, their current asset > current liabilities and their Free Cash Flow can deal with their debts (i.e if they decided to pay off all of that debt, they could)
Pipeline on phase 3 there are 25 products and 3 products under review (one of them is Anti-Viral COVID-19
molnupiravir (MK-4482) (US, EU))
-source : their website
On the technicals, price is trading below the 100-200 EMA. The TSI shadow indicator still suggest we are still in a downtrend. As far as I am concerned, the lower the share price will go, the better. As long as the fundamentals still as it is now, I am happy the share price to go lower.
I take note of last week's high as a level of interest as if this level is broken, it could be a sign of a momentum shift.
Are Pfizer, Merck and Moderna Still Worthy to Be in Portfolio?Pfizer is now outperforming Merck and Moderna stocks after announcing its anti-COVID pill despite its shares not being the best option for investments in the first half of this year. Pfizer stocks gained only 35% since the beginning of this year until mid-August. Moderna stocks were skyrocketed by 375% for the same period. So, undoubtedly Moderna was the favourite.
However, when Merck announced the production of its COVID pills, the shares of vaccine producers spiraled into correction. But Merck was not the one to get its COVID pills into the market. Its shares peaked up to $91.40 and plunged with a gap after Pfizer announced its even more promising COVID treatment pills. The company said clinical trials showed that hospitalisation and deaths were reduced by 89% when the pill is taken within three days of the onset of symptoms.
So, this news from Pfizer came on November 5 and since then the technical picture for the above-mentioned three Big Pharma stocks changed dramatically. Pfizer shares are taking the lead while waving away all their August corrections and now they are close to the all-time highs at $51.86. If they are successful at breaking through this level, technical price acceleration may bring its stocks to $56.03 and $58.60 may be the next target. These levels could be a correction impulse to the decline from $51.86 to $40.94 per share. The nearest support level is at $47.70-48.80.
As for Moderna stocks, the last quarter financial report hit them badly. Nevertheless, impulsive selloffs are now over as shares dipped to the important support level established in November 2020. So, now it is worth consider buying these shares. Corrections went into an ABC zigzag and shares are likely to return on the upside track. Initially, A and B waves were suggested to be equal, but now we see that the C wave is 161.8% of the A wave that gave us a decline to $225.85 per share. In my opinion Moderna shares have accomplished their correction and are close to the trend line of the last 12 month, and for that reason are an interesting investment. So, Moderna stocks may even be catching up to Pfizer. The nearest targets for Moderna stocks are within the area of $283-291 where EMA 21 moving average is located at the daily timeframe chart together with the resistance level formed by dips of July and October 2021. Moreover, at the $298 landmark, the resistance line of the downward trend that started on September 23 is located. If this zone would be broken the perspectives for Moderna stocks should be extended.Despite all these different technical pictures for these stocks, I would recommend holding all three stocks in your investment portfolio. Pfizer and Merck continue to compete in the COVID pills market while Moderna has a forward P/E ratio at 9, which highlights that the company is the cheapest among the Big Pharma biotech companies if compared with its peers sector performance.
MERCK ANALYSISI would like to see MERCK pull back to $81-82 range. With news coming out of FDA approval of their COVID pill it will be a quick spike to the 85-95 range and then a pullback. Approval should happen the first or second week of December. Looking at options calls for $83 if stock pulls back to $81-82.
Merck Stocks Have a 25% Growth PotentialToday we will review Merck & Co stocks as I have promised recently. The company announced the launch of the first oral medication against COVID-19 with proven efficiency.
Let’s analyse the chart with the Merck stocks and their upside potential.
When doing analysis it is traditionally better to start from the eldest timeframes to distinguish the existing trend. So, if we look at the monthly timeframe chart of Merck stocks we may find an upward trend that started in March 2009. We may also see a consolidation since January 2020 that lasted until September 2021, that is forming a triangle. This figure acts as a continuation sequence of the trend as the upward breakthrough has already been made. The breakthrough occurred on October 1, when the company announced successful clinical trial results of its anti-COVID-19 pill.
This announcement was made a week before and no other news has been announced concerning this. This triangle provides a potential for Merck stocks to go to the $103.50-104 area. So, it is a potential gain of 25-26% from the current price. Moreover, the gap on October 1 is now acting as a key support level. Nevertheless, technically we may have a retest of the upper triangle margin at the $78.50-$79.30 area. But even if this retest does not happen, as it is not always the case, it is worth to consider adding these stocks to the portfolio.
It should be noted that this technical pattern has been forming for several months and we should expect that the upside scenario would be effective for a while still. It may take 2-3 month, or even more, to reach the mentioned targets. However, such long-term technical patterns usually provide a good profit for those who are not looking for a checkered fortune.Merck has made contracts to deliver its pills not only in the United States, but also with other governments that are currently considering purchasing this new medication.